Emerging Data Help Steer CDK4/6 Inhibitor Choice in HR+/HER2

Karen S. Anderson, MD, PhD, discusses emerging data and role for CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive, HER2-negative breast cancer, along with the growing use of antibody-drug conjugates across the breast cancer spectrum and updates in triple-negative breast cancer.

Related Keywords

Minnesota , United States , Felipe Batalini , Karens Anderson , Lidaa Mina , Banner Md Anderson Cancer Center , Mayo Clinic Comprehensive Cancer Center , Science Summit , Mayo Clinic Comprehensive Cancer , Shakeela Bahadur , Cancer Center , Cdk4 6 Inhibitors , Breast Cancer , Hr Positive Breast Cancer , Ntnbc , Triple Negative Breast Cancer , Antibody Drug Conjugates , Mayo Clinic ,